Results 231 to 240 of about 1,436,444 (347)

Cord Blood‐Derived Fibroblast Activation Protein‐Targeted Chimeric Antigen Receptor Natural Killer Cells Persist in Vivo

Cancer Science, EarlyView.
We generated cord blood‐derived FAP‐targeted CAR NK cells and evaluated their activity against cancer‐associated fibroblasts. These cells showed antigen‐specific cytotoxicity in vitro and robust persistence in a pleural dissemination model, although in vivo anti‐CAF efficacy was limited, supporting further development of stromal‐targeted cellular ...
Takashi Hiroshima, Toru Kimura, Mariko Maekawa, Mayuko Noguchi, Takahiro Matsui, Shunya Ikeda, Makiko Suga, Hideki Nagata, Kenji Kimura, Eriko Fukui, Takashi Kanou, Naoko Ose, Eiichi Morii, Yasushi Shintani, Naoki Hosen   +14 more
wiley   +1 more source

BAFF and APRIL signaling in the B-cell lineage: implications for the pathogenesis of ANCA-associated vasculitis. [PDF]

Front Immunol
Shimojima Y, Yoshida S, Matsumoto H, Sumichika Y, Asano T, Sato S.   +5 more
europepmc   +1 more source

Chimeric antigen receptor T-cell therapy in neuroimmune diseases: mechanistic rationale, clinical experience, and translational challenges. [PDF]

Front Immunol
Yi Y, Xiao H, Yin Y, Zeng R, Yan Q, Wu Y, Yang K, Fu G, Xu H, Zhang X.   +9 more
europepmc   +1 more source

Aberrant Expression of Multiple T‐Cell Markers in Primary Cutaneous Follicle Center Lymphoma: A Rare Case Report

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Aberrant expression of T‐cell markers in B‐cell lymphomas is rare and can pose diagnostic challenges. We report a case of a 65‐year‐old man presenting with newly developed scalp nodules. Histopathology revealed nodular lymphoid infiltrates composed of large centrocytes and centroblasts.
V. Pfefferle, A. Vogelsberg, M. Maaß, C. M. Schürch, S. Forchhammer   +4 more
wiley   +1 more source

Chimeric antigen receptor T-cell therapy in systemic lupus erythematosus: From B cell depletion to immune reprogramming. [PDF]

J Transl Autoimmun
Zhao W, Chen M, Long J, Lu P, Jin J.
europepmc   +1 more source

Bullous Eruption Associated With Loncastuximab Tesirine in a Patient With Diffuse Large B‐Cell Lymphoma

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Loncastuximab tesirine (LT) is an antibody‐drug conjugate (ADC), a novel class of therapeutics that combines a target‐specific monoclonal antibody with a cytotoxic agent via a chemical linker. LT has been approved in the United States as therapy for relapsed or refractory diffuse large B‐cell lymphoma (DLBCL).
Daniella Jaguan, Cuong Nguyen, Jennifer N. Choi   +2 more
wiley   +1 more source

Dual B -Cell Maturation Antigen/CD19 Chimeric Antigen Receptor- T Therapy for AL Amyloidosis : Targeting the Clone, Saving the Kidney. [PDF]

J Am Soc Nephrol
Sobczak K, Leick MB.
europepmc   +1 more source

InflaMix Predicts Severe CRS, ICU Admission, and Progression‐Free Survival After CAR‐T Therapy in LBCL

European Journal of Haematology, EarlyView.
ABSTRACT Objectives Baseline systemic inflammation has emerged as a determinant of outcome after CD19‐directed CAR‐T therapy. We evaluated the prognostic performance of the recently developed INFLAmmation MIXture Model (InflaMix) in an independent bicentric cohort of patients with large B‐cell lymphoma (LBCL) receiving commercial CAR‐T cells, focusing ...
Eugenio Galli, Daniele Mannina, Alessandro Corrente, Chiara De Philippis, Ilaria Pansini, Marcello Viscovo, Stefan Hohaus, Patrizia Chiusolo, Federica Sorà, Stefania Bramanti, Simona Sica   +10 more
wiley   +1 more source

Mechanisms, optimization strategies, and salvage options for CAR-T cell therapy. [PDF]

Biomark Res
Wu B, Wang J, Zou Q, Cai J, Zhang Y, Zhong Q, Bai B, Liu F, Cao Y, Li P, Dai DL, Cai Q.   +11 more
europepmc   +1 more source

Flow cytometric identification of plasmacytoid dendritic cells in acute myeloid leukaemia: Challenges and practical considerations

British Journal of Haematology, EarlyView.
Mariana S. Vieira, Pietro B. Belmonte, Natália A. Marcondes, Raquel Q. Vidal, Flavo B. Fernandes, Liane N. Rotta   +5 more
wiley   +1 more source